Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vabicaserin in acute exacerbations of schizophrenia
NCT00563706Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of vabicaserin in schizophrenia (3 arms), sponsored by Pfizer. Primary endpoint: Positive and Negative Symptom Scale Total Score at Day 28. Started Dec 2007; status: completed.
02
Drugs
vabicaserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00563706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563706.